Haemonetics Corporation earnings releases HAE

Haemonetics Corporation last reported quarterly results on Nov 5, 2026, for Q2 FY2027 (the quarter ended Sep 26, 2026): revenue of $357.8 million (+9.3% year over year) and diluted EPS of $1.00. It usually reports 40 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 4, 2027.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 40 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Nov 5, 2026
40 days after quarter end
Q2 FY2027
ended Sep 26, 2026
358
+9.3%
46
+19.7%
1.00
+23.5%
Aug 6, 2026
40 days after quarter end
Q1 FY2027
ended Jun 27, 2026
339
+5.6%
33
-3.0%
0.72
+2.9%
May 7, 2026
40 days after quarter end
Q4 FY2026
ended Mar 28, 2026
346
+4.8%
-20
-134.7%
-0.43
-137.0%
Feb 5, 2026
40 days after quarter end
Q3 FY2026
ended Dec 27, 2025
339
-2.7%
45
+19.3%
0.95
+28.4%
Nov 6, 2025
40 days after quarter end
Q2 FY2026
ended Sep 27, 2025
327
-5.3%
39
+14.3%
0.81
+22.7%
Aug 7, 2025
40 days after quarter end
Q1 FY2026
ended Jun 28, 2025
321
-4.4%
34
-11.3%
0.70
-5.4%
May 8, 2025
40 days after quarter end
Q4 FY2025
ended Mar 29, 2025
331
-3.7%
58
+184.7%
1.17
+195.8%
Feb 6, 2025
40 days after quarter end
Q3 FY2025
ended Dec 28, 2024
349
+3.7%
37
+20.0%
0.74
+21.3%

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
HAE (NYSE)
Fiscal year ends
April 3
Incorporated in
MA
Headquarters
Boston, MA
SEC filer status
Large accelerated filer
SEC CIK
313143

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.